Roivant brings Pfiz­er vets Azoulay, Gul­fo in­to its C-suite; Aileron CEO Joseph Yanchik is out

Sa­lomon Azoulay

Vivek Ra­maswamy has ush­ered two Pfiz­er vets in­to Roivant’s C-suite as he con­tin­ues to build his vi­sion for a Vant king­dom. New CMO Sa­lomon Azoulay most re­cent­ly held the same role at Pfiz­er Es­sen­tial Health, the busi­ness unit in charge of a slate of mar­ket­ed drugs. Adele Gul­fo, who’s now chief of com­mer­cial de­vel­op­ment, got her start launch­ing Lip­i­tor and used to run the busi­ness de­vel­op­ment for As­traZeneca be­fore join­ing Pfiz­er.

Adele Gul­fo

Roivant not so long ago upped its in­volve­ment in both Chi­na and the in­fec­tious dis­ease mar­ket by bag­ging rights to Nabri­va’s lefa­mulin in the re­gion. And then there was the launch of Genevant just a month ago, born out of a part­ner­ship with the RNAi spe­cial­ists at Ar­bu­tus. With Ax­o­vant’s spec­tac­u­lar fail­ure in Alzheimer’s still fresh in every­one’s mind, it’s a crit­i­cal time for CEO Ra­maswamy, a skilled fundrais­er and fi­nan­cial en­gi­neer, to prove he is equal­ly good in ac­tu­al­ly de­liv­er­ing new drugs.

“As the scale and scope of our pipeline con­tin­ue to grow and we ap­proach com­mer­cial­iza­tion for sev­er­al ther­a­pies across the Vants, Sam and Adele will work to en­sure that our med­i­cines reach pa­tients as quick­ly as pos­si­ble,” said Ra­maswamy in a state­ment.

→ Hav­ing steered Aileron Ther­a­peu­tics $AL­RN in­to clin­i­cal stage and through an IPO, Joseph Yanchik is leav­ing his com­pa­ny of 12 years and all his roles, in­clud­ing pres­i­dent, CEO and board mem­ber. Bio­phar­ma con­sul­tant and two-time CEO John Lon­ge­neck­er has been brought in to fill the role on an in­ter­im ba­sis. The Cam­bridge, MA-based biotech did not give a rea­son for Yanchik’s sud­den de­par­ture in its press re­lease, choos­ing in­stead to high­light mid-stage clin­i­cal plans for its lead on­col­o­gy can­di­date. A ven­ture part­ner at Ap­ple Tree, Yanchik had helped found Aileron in 2005.

Bryan Irv­ing

Genen­tech vet Bryan Irv­ing just got a pro­mo­tion at Five Prime Ther­a­peu­tics $FPRX, where he will now be EVP and CSO. Irv­ing, a key re­searcher in the de­vel­op­ment of Tecen­triq, has a broad man­date to set dis­cov­ery strat­e­gy and pri­or­i­ties for Five Prime’s im­muno-on­col­o­gy pro­tein ther­a­peu­tics pipeline. Pri­or to join­ing the South San Fran­cis­co biotech, he spent sev­er­al years di­rect­ing can­cer im­munol­o­gy at Cy­tomX.

→ Phase I da­ta in hand, Sen­sei Bio­ther­a­peu­tics has named John Celebi pres­i­dent and CEO to ce­ment its im­muno-on­col­o­gy plat­form and be the face of its new iden­ti­ty (un­til ear­li­er this year, the com­pa­ny was known as Panacea Phar­ma­ceu­ti­cals). Celebi paid his dues as COO of X4 Phar­ma­ceu­ti­cals and CBO of Igeni­ca Bio­ther­a­peu­tics, lead­ing — re­spec­tive­ly — their on­col­o­gy and im­munother­a­py pro­grams. He brings a string of deal­mak­ing and al­liance man­age­ment records to Gaithers­burg, MD-based Sen­sei, where his ini­tial pri­or­i­ty will be lead drug can­di­date SNS-301, a can­cer vac­cine de­vel­oped with the SPIR­IT plat­form which tar­gets neoanti­gens or al­tered self-anti­gens en­cod­ed by tu­mor-spe­cif­ic mu­tant genes.

→ Af­ter co-found­ing and lead­ing gener­ics com­pa­ny Am­neal Phar­ma­ceu­ti­cals for 15 years, Chin­tu Pa­tel is set­ting his sight on biosim­i­lars. He is now the CEO of Adel­lo Bi­o­log­ics, a mon­o­clon­al an­ti­body spe­cial­ist head­quar­tered in Pis­cat­away, NJ and cur­rent­ly fo­cused on can­cer. He suc­ceeds Pe­ter Moes­ta, Adel­lo’s CEO for al­most three years.

→ Di­a­betes ex­pert Pawel Fludzin­s­ki has jumped from Eli Lil­ly to the helm of Amide­Bio. He re­places found­ing CEO Misha Plam, who will re­main as pres­i­dent and chair­man of the board. “Amide­Bio’s nov­el ap­proach to de­vel­op­ing glu­cose re­spon­sive in­sulins (GRI) promis­es to rad­i­cal­ly im­prove di­a­betes treat­ment,” said Fludzin­s­ki in a state­ment. “I look for­ward to lead­ing the GRI ef­fort as well as oth­er growth op­por­tu­ni­ties.” Dur­ing his lengthy tenure at Lil­ly, Fludzin­s­ki led a cross-func­tion­al team work­ing through late-stage stud­ies and glob­al reg­is­tra­tion of Trulic­i­ty — a key fran­chise for its di­a­betes busi­ness unit.

→ For­mer Ac­er­ta Phar­ma ex­ec Fran­cis­co Sal­va is tak­ing his fi­nance and op­er­a­tion ex­per­tise to the CEO post at Com­plexa. The Berwyn, PA-based com­pa­ny is de­vel­op­ing a drug dubbed CXA-10 in pul­monary ar­te­r­i­al hy­per­ten­sion and fo­cal seg­men­tal glomeru­loscle­ro­sis — both or­phan in­di­ca­tions — and has tasked Sal­va with ad­vanc­ing its Phase II de­vel­op­ment. Sal­va, who worked as a VC be­fore mov­ing on to start Ac­er­ta, is al­so ex­pect­ed to beef up the pipeline with more next-gen ni­trat­ed fat­ty acid com­pounds to treat fi­brot­ic and in­flam­ma­tion based dis­eases.

Jeanne Ma­gram

Quen­tis Ther­a­peu­tics has put its $48 mil­lion of Se­ries A dol­lars to use, re­cruit­ing Jeanne Ma­gram back to New York City from Toron­to’s North­ern Bi­o­log­ics. As CSO, Ma­gram will build on the young biotech’s sci­en­tif­ic foun­da­tion about the en­do­plas­mic retic­u­lum (ER) path­ways — with sci­ence com­ing out of Lau­rie Glim­ch­er’s lab at Dana Far­ber — guid­ing drug dis­cov­ery and de­vel­op­ment in “im­muno-on­col­o­gy and be­yond.” While the spot­light now goes to a small mol­e­cule IRE1α in­hibitor sched­uled to en­ter the clin­ic in 2019, a pipeline of pre­clin­i­cal pro­grams is ex­pect­ed to fol­low. That kind of ear­ly stage work is the sweet spot for Ma­gram, who pre­vi­ous­ly led Pfiz­er’s Cen­ters for Ther­a­peu­tic In­no­va­tion and did drug dis­cov­ery work at Boehringer In­gel­heim.

→ Af­ter tack­ling a num­ber of on­col­o­gy pro­grams at Astel­las Phar­ma, Pfiz­er and Eli Lil­lyStephen Eck will now ze­ro in on T cell ther­a­pies as CMO of Im­mat­ics. The biotech is based in Hous­ton, with sub­stan­tial ties to the MD An­der­son Can­cer Cen­ter — a col­lab­o­ra­tor Eck has got­ten to know while co­or­di­nat­ing clin­i­cal tri­als for Astel­las. Eck is tasked with steer­ing the pre­clin­i­cal-heavy pipeline to­ward clin­i­cal de­vel­op­ment.

Ray­mond Ur­ban­s­ki is get­ting pro­mot­ed to pres­i­dent at GT Bio­phar­ma, on top of the CMO role that he’s been in for about eight months. Ac­cord­ing to CEO Shawn Cross, that re­flects the crit­i­cal con­tri­bu­tions that Ur­ban­s­ki has made to the im­muno-on­col­o­gy biotech, rang­ing from sci­en­tif­ic and clin­i­cal ac­tiv­i­ties to tal­ent re­cruit­ment and in­ter­nal process man­age­ment. While the ex­pe­ri­enced CMO had played sim­i­lar roles at his for­mer work­places, in­clud­ing Pfiz­er, My­lan and MannKind, this marks his first time be­ing pres­i­dent of a com­pa­ny.

Astel­las is hand­ing Bern­hardt Zei­her, cur­rent­ly pres­i­dent of de­vel­op­ment, the ad­di­tion­al role of CMO. The pro­mo­tion means Zei­her will now be re­spon­si­ble for qual­i­ty as­sur­ance in re­search and clin­i­cal ac­tiv­i­ties, plan­ning and ad­min­is­tra­tion, as well as reg­u­la­to­ry af­fairs. A Pfiz­er vet, Zei­her joined Astel­las’ North­brook, IL head­quar­ters as a leader of its in­flam­ma­tion, im­munol­o­gy and in­fec­tious dis­eases unit. He now has a much broad­er man­date re­gard­ing the whole pipeline — part of a cor­po­rate strate­gic plan de­vised by new­ly mint­ed CEO Ken­ji Ya­sukawa.

→ Faced with a grow­ing cri­sis over its $1.2 mil­lion in pay­ments to Pres­i­dent Don­ald Trump’s per­son­al at­tor­ney Michael Co­hen, No­var­tis $NVS an­nounced ear­ly Wednes­day that the com­pa­ny’s top lawyer has abrupt­ly re­signed in hopes of bring­ing the whole tawdry af­fair to an end. “Al­though the con­tract (with Co­hen) was legal­ly in or­der, it was an er­ror,” said Fe­lix Ehrat, group gen­er­al coun­sel of No­var­tis, in a state­ment. “As a co-sig­na­to­ry with our for­mer CEO, I take per­son­al re­spon­si­bil­i­ty to bring the pub­lic de­bate on this mat­ter to an end.”

→ With its Epi­tope-Spe­cif­ic Im­muno-Ther­a­py plat­form, Im­mu­sanT has wooed Ken Tru­itt away from Dai­ichi Sankyo to be­come its CMO. Though Tru­itt is ini­tial­ly fo­cused on the Phase II clin­i­cal de­vel­op­ment for Nex­vax2 in celi­ac dis­ease, CEO Leslie Williams hired him with the long view in mind, bank­ing on his ex­pe­ri­ence from pre­clin­i­cal up to NDA. The Arch-backed start­up plans to ex­plore its tech in oth­er au­toim­mune dis­eases in­clud­ing type 1 di­a­betes.

→ In a bid to emerge as a “glob­al, mul­ti-prod­uct on­col­o­gy com­pa­ny,” Seat­tle Ge­net­ics $SGEN has tapped Roger Dansey — a for­mer Mer­ck ex­ec of Keytru­da fame — as CMO. Pre­vi­ous­ly the ther­a­peu­tic head for late-stage on­col­o­gy at Mer­ck, Dansey in­her­its fran­chise drug Ad­cetris and a slate of ear­ly- to mid-stage drugs from long­time CMO Jonathan Drach­man. Ad­cetris was re­cent­ly ap­proved for front­line Hodgkin lym­phoma, its fifth in­di­ca­tion, with plans for more. The com­pa­ny is count­ing on Dansey’s de­vel­op­ment and ap­proval ex­pe­ri­ence, dat­ing back from his Gilead and Am­gen days, to dri­ve suc­cess­ful piv­otal tri­als for oth­er can­cer drugs in its bas­ket, some of which it picked up from the $614 mil­lion Cas­ca­di­an buy­out pact ex­e­cut­ed in Jan­u­ary. Drach­man will be on hand as a strate­gic ad­vis­er.   

Rodin Ther­a­peu­tics has re­cruit­ed three new ex­ecs in its quest to tack­le synap­tic re­silience in Alzheimer’s dis­ease — and be­yond. Michael Ryan, a physi­cian-sci­en­tist with neu­ro­science re­search back­grounds in No­var­tis and Pfiz­er, has been named CMO; Ex-Sunovion ex­ec Anne Sul­li­van will lead cor­po­rate strat­e­gy as CBO; Steven Sweeney, for­mer­ly of In­fin­i­ty Phar­ma and Arteaus Ther­a­peu­tics, is now VP of clin­i­cal de­vel­op­ment op­er­a­tions. Guid­ing their ef­forts will be David Bleak­man, a long­time Eli Lil­ly re­search ex­ec who’s joined the sci­en­tif­ic ad­vi­so­ry board.

→ A new ap­point­ment has brought glo­be­trot­ter Ralph Laufer to Cam­bridge, MA and Paris, where he will run gene ther­a­py pro­grams as CSO of Lyso­gene. Pri­or to join­ing the biotech, which fo­cus­es on or­phan dis­ease of the cen­tral ner­vous sys­tem, Laufer man­aged small mol­e­cule dis­cov­ery and non­clin­i­cal de­vel­op­ment for Is­rael’s Te­va — and that’s af­ter di­rect­ing a sci­ence park for a CRO in Italy.

Eliel Bayev­er has land­ed his first CMO role at Cana­da’s On­co­Quest, con­tin­u­ing his ca­reer-long in­volve­ment with on­col­o­gy ther­a­peu­tics. With an im­munother­a­py as­set in var­i­ous stages of de­vel­op­ment for dif­fer­ent in­di­ca­tions, the com­pa­ny is count­ing on Bayev­er’s ex­per­tise in both ear­ly and late stage clin­i­cal stud­ies to move its ovar­i­an, pan­cre­at­ic and breast can­cer pro­grams along. For Bayev­er, for­mer­ly of J&J and Mer­ri­mack, the po­ten­tial that ore­gov­omab has shown for front­line ovar­i­an can­cer in Phase II is the most ex­cit­ing.

TP Ther­a­peu­tics has brought in in­dus­try vet­er­an Athena Coun­tou­ri­o­tis as EVP and CMO. In ad­di­tion to her ex­ten­sive ex­pe­ri­ence in the job — hav­ing served in the role at Ad­verum, Halozyme and Am­bit — the Or­bimed-backed biotech al­so likes their align­ment in the ki­nase in­hibitor area. As San Diego-based TP Ther­a­peu­tics un­veils Phase I da­ta for lead as­set TPX-0005 (ropotrec­tinib), Coun­tou­ri­o­tis will help dri­ve strat­e­gy for this and oth­er pro­grams ad­dress­ing re­sis­tance to onco­gene tar­get­ing can­cer treat­ments.

→ New Haven, CT-based Tre­vi Ther­a­peu­tics has ap­point­ed Christo­pher Seit­er as CFO, putting all fi­nan­cial, trea­sury and ac­count­ing func­tions in his hands as it pur­sues late-stage stud­ies of Nal­buphine ER in chron­ic pru­rit­ic con­di­tions. An in­vest­ment banker of 23 years, Seit­er made the jump to biotech op­er­a­tions a cou­ple years back at Mil­len­do Ther­a­peu­tics.

Kei­th Ven­dola is bring­ing his in­vest­ment bank­ing back­ground to Re­zo­lute, a meta­bol­ic and or­phan dis­eases com­pa­ny based in Col­orado. With two as­sets in Phase I and II, along­side plans to file an IND this year, the com­pa­ny be­lieves Ven­dola’s ex­per­tise in fi­nance and deal­mak­ing could come in­to play.

Liq­uidia Tech­nolo­gies is al­ready think­ing about com­mer­cial­iza­tion for its pul­monary ar­te­r­i­al hy­per­ten­sion treat­ment, and it has re­cruit­ed Jeri Thomas to de­vel­op those plans as SVP, com­mer­cial. Her march­ing or­ders will be to lead the launch of LIQ861, cur­rent­ly be­ing eval­u­at­ed in a Phase III safe­ty tri­al. Be­fore jump­ing to a mar­ket­ing agency, Thomas made her rounds from Bris­tol-My­ers Squibb and Roche to Janssen and The Med­i­cines Com­pa­ny, in a va­ri­ety of com­mer­cial roles.

→ Wall Street an­a­lyst Michael King has made the jump to biotech, tak­ing up the po­si­tion of en­tre­pre­neur in res­i­dence at Fortress Bio’s $FBIO NYC of­fices. He is ex­pect­ed to lever­age his eye for promis­ing ther­a­pies and knowl­edge about cor­po­rate struc­tures to help ex­pand Fortress Bio’s port­fo­lio in on­col­o­gy and un­der-the-radar dis­eases, adding to its 10 sub­sidiaries and over 25 de­vel­op­ment-stage ther­a­pies.

Rock­et Phar­ma­ceu­ti­cals $RCKT has named Gay­a­tri Rao its first VP of reg­u­la­to­ry pol­i­cy and pa­tient ad­vo­ca­cy. Lean­ing on her ex­pe­ri­ence as a for­mer di­rec­tor of the FDA’s Of­fice of Or­phan Prod­ucts De­vel­op­ment, Rao will be trust­ed for di­rec­tion to glob­al reg­u­la­to­ry poli­cies and strate­gies for Rock­et’s rare dis­ease pro­grams, some of which have read­outs this week.

Regeneron CEO Leonard Schleifer speaks at a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House (AP Photo/Andrew Harnik)

OWS shifts spot­light to drugs to fight Covid-19, hand­ing Re­gen­eron $450M to be­gin large scale man­u­fac­tur­ing in the US

The US government is on a spending spree. And after committing billions to vaccines defense operations are now doling out more of the big bucks through Operation Warp Speed to back a rapid flip of a drug into the market to stop Covid-19 from ravaging patients — possibly inside of 2 months.

The beneficiary this morning is Regeneron, the big biotech engaged in a frenzied race to develop an antibody cocktail called REGN-COV2 that just started a late-stage program to prove its worth in fighting the virus. BARDA and the Department of Defense are awarding Regeneron a $450 million contract to cover bulk delivery of the cocktail starting as early as late summer, with money added for fill/finish and storage activities.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Noubar Afeyan, Flagship CEO and Tessera chairman (Victor Boyko/Getty Images)

Flag­ship ex­ecs take a les­son from na­ture to mas­ter ‘gene writ­ing,’ launch­ing a star-stud­ded biotech with big am­bi­tions to cure dis­ease

Flagship Pioneering has opened up its deep pockets to fund a biotech upstart out to revolutionize the whole gene therapy/gene editing field — before gene editing has even made it to the market. And they’ve surrounded themselves with some marquee scientists and execs who have crowded around to help shepherd the technology ahead.

The lead player here is Flagship general partner Geoff von Maltzahn, an MIT-trained synthetic biologist who set out in 2018 to do CRISPR — a widely used gene editing tool — and other rival technologies one or two better. Von Maltzahn has been working with Sana co-founder Jake Rubens, another synthetic biology player out of MIT who he describes as his “superstar,” who’s taken the CSO role.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Squab­bles with gov­ern­ment de­lay Mod­er­na’s PhI­II — re­ports; No­vavax se­cures largest Warp Speed deal yet: $1.6B

A much-anticipated Phase III trial for Moderna’s Covid-19 vaccine is being held up as the company delayed submitting trial protocols and sparred with government scientists on how to run the study and even what the benchmark for success should be, Reuters reported.

Moderna, the first US company to put their vaccine into human testing, was supposed to enter a 30,000-person study this month in partnership with the NIH to determine whether it can prevent infection. STAT reported last week that the trial was facing delays over the protocol, but that a July start was still possible. Neither the NIH nor Moderna ever disclosed a specific date the trial should start, but Reuters reported that the agency had hoped to begin on July 10.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Donald and Melania Trump watch the smoke of fireworks from the South Lawn of the White House on July 4, 2020 (via Getty)

Which drug de­vel­op­ers of­fer Trump a quick, game-chang­ing ‘so­lu­tion’ as the pan­dem­ic roars back? Eli Lil­ly and Ab­Cellera look to break out of the pack

We are unleashing our nation’s scientific brilliance and will likely have a therapeutic and/or vaccine solution long before the end of the year.

— Donald Trump, July 4

Next week administration officials plan to promote a new study they say shows promising results on therapeutics, the officials said. They wouldn’t describe the study in any further detail because, they said, its disclosure would be “market-moving.”

— NBC News, July 3

Something’s cooking. And it’s not just July 4 leftovers involving stale buns and uneaten hot dogs.

Over the long weekend observers picked up signs that the focus in the Trump administration may swiftly shift from the bright spotlight on vaccines being promised this fall, around the time of the election, to include drugs that could possibly keep patients out of the hospital and take the political sting out of the soaring Covid-19 numbers causing embarrassment in states that swiftly reopened — as Trump cheered along.

So far, Gilead has been the chief beneficiary of the drive on drugs, swiftly offering enough early data to get remdesivir an emergency authorization and into the hands of the US government. But their drug, while helpful in cutting stays, is known for a limited, modest effect. And that won’t tamp down on the hurricane of criticism that’s been tearing at the White House, and buffeting the president’s most stalwart core defenders as the economy suffers.

We’ve had positive early-stage vaccine data, most recently from Pfizer and BioNTech, playing catchup on an mRNA race led by Moderna — where every little sign of potential trouble is magnified into a lethal threat, just as every advance excites a frenzy of support. But that race still has months to play out, with more Phase I data due ahead of the mid-stage numbers looming ahead. A vaccine may not be available in large enough quantities until well into 2021, which is still wildly ambitious.

So what about a drug solution?

Trump’s initial support for a panacea focused on hydroxychloroquine. But that fizzled in the face of data underscoring its ineffectiveness — killing trials that aren’t likely to be restarted because of a recent population-based study offering some support. And there are a number of existing drugs being repurposed to see how they help hospitalized patients.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Cel­lec­tis slammed af­ter pa­tient dies and FDA slaps a hold on their tri­al for an off-the-shelf CAR-T for mul­ti­ple myelo­ma

Cellectis was slammed after the market close on Monday as the biotech reported that the FDA demanded it hit the brakes on their MELANI-01 trial for their off-the-shelf cell therapy UCARTCS1A after one of the patients in the study died of treatment-related cardiac arrest.

The multiple myeloma patient had previously been treated unsuccessfully with various therapies, noted the biotech, and had been given dose level two (DL2) of their allogeneic CAR-T.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Shoshanna Shendelman, Applied Therapeutics CEO (Applied Therapeutics)

A lit­tle biotech slaps back at a 'crim­i­nal' short at­tack, vow­ing to pur­sue a pros­e­cu­tion of their case

As short attacks go, Biotech Research Partners’ assault on Applied Therapeutics’ “cherry picked” data and a variety of so-called red flags didn’t cause a whole lot of damage. Ahead of the July 4 holiday, its shares $APLT were dinged and showed signs of quick recovery.

But that didn’t stop an incendiary response, as the biotech swung into action bright and early Monday morning.

Applied Therapeutics accused the authors of the short report of manipulating graphs and figures, misrepresenting data and included factual misrepresentations — all of which added up, in their view, to fraud.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Bill Haney, Dragonfly CEO (Dave Pedley/Getty Images for SXSW)

A boom­ing Drag­on­fly is tak­ing its TriN­KETs to Copen­hagen as the lat­est Bris­tol My­ers pact spurs ex­pan­sion plans — out­side the US

Bristol Myers Squibb is making a habit out of collaborating with the crew at Dragonfly, adding their 3rd deal in a series that now will take them into newly charted R&D territory. And the fast-growing team at the Cambridge-based biotech is adding a facility in Copenhagen for its next growth spurt, where the government is making it easy to recruit scientists internationally as the U.S. throttles back.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Teamed up with NIH, Re­gen­eron launch­es PhI­II pre­ven­tion tri­al for an­ti­body cock­tail

As Regeneron moves its antibody cocktail into Phase II/III trials testing REGN-COV2 as a treatment for both hospitalized and non-hospitalized patients with Covid-19, the biotech is also starting a Phase III in the prevention setting.

The National Institute of Allergy and Infectious Diseases — which orchestrated the large, randomized study for remdesivir that produced positive results — will jointly run the study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Douglas Love, Annexon CEO (Annexon)

IPO bound? Ac­tu­al­ly, An­nex­on was al­ready prepped and primed to toss its S-1 to Wall Street as in­vestors ral­lied

The Wall Street IPO shuffle generally calls for a little distance between the crossover ante and the Wall Street double, but with the window on the street wide open and biotech sizzling hot, who’s waiting?

The crew at Annexon didn’t leave anyone in suspense for long about their IPO plans. A day after the Bay Area biotech with clinical plans to target neurodegeneration quietly unveiled a $100 million raise, they were back with an S-1 outlining a pitch to double that — or more.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.